Table of Contents
Volume 7 | Issue 3
Publication Date: November 2005- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Editorial | ||
154-155 |
Treatment Options for Patients with Advanced-Stage Non–Small-Cell Lung Cancer: Who Are the “Elderly” and Who Are the “Unfit”? David R. Gandara, Paul Hesketh |
|
Researches in Brief | ||
163-165 |
Relevance of Epidermal Growth Factor Receptor Genomic Gain in Predicting Clinical Response to Kinase Inhibitors in Non–Small-Cell Lung Cancer G. Kesava Reddy, Vinay K. Jain |
|
166-167 |
Noninvasive Visualization of Apoptosis Using Radiolabeled Annexin V Could Predict Response to Chemotherapy G. Kesava Reddy, Eric Nadler, Vinay K. Jain |
|
Comprehensive Reviews | ||
168-174 |
Undertreatment of Elderly Patients with Non–Small-Cell Lung Cancer Raymond Ng, Richard de Boer, Michael D. Green |
|
175-179 |
Vascular-Targeting Agents and Radiation Therapy in Lung Cancer: Where Do We Stand in 2005? David Raben, Anderson Ryan |
|
Original Contributions | ||
180-182 |
Influence of Sex on Lung Cancer Histology, Stage, and Survival in a Midwestern United States Tumor Registry Geoffrey Ringer, J. Michael Smith, Amy M. Engel, Mary Pat Hendy, Janet Lang |
|
183-189 |
Sequential Versus Alternating Administration of Cisplatin/Etoposide and Topotecan as First-Line Treatment in Extensive-Stage Small-Cell Lung Cancer: Preliminary Results of a Phase III Trial of the Hellenic Oncology Research Group Michail Ignatiadis, Dimitris Mavroudis, Marinos Veslemes, John Boukovinas, Kostas Syrigos, Maria Agelidou, Athina Agelidou, Aleka Gerogianni, Georgia Pavlakou, Evaggelos Tselepatiotis, John Nikolakopoulos, Vassilis Georgoulias |
|
190-196 |
Topotecan in the Treatment of Elderly Patients with Relapsed Small-Cell Lung Cancer Jennifer Garst, Richard Buller, Stephen Lane, Jeffrey Crawford |
|
197-201 |
Patterns of Recurrence and Long-Term Survival After Curative Resection of Localized Fibrous Tumors of the Pleura Ricardo S. Santos, Rui Haddad, Carlos E. Lima, Yu Lin Liu, Margareth Misztal, Tadeu D. Ferreira, Carlos H. Boasquevisque, James D. Luketich, Rodney J. Landreneau |
|
202-207 |
Gemcitabine/Carboplatin in Patients with Metastatic Non–Small-Cell Lung Cancer: Phase II Study of 28-Day and 21-Day Schedules Coleman K. Obasaju, Zhishen Ye, Leslie P. Bloss, Matthew J. Monberg, Rafael E. Curiel |
|
208-214 |
Randomized Multicenter Phase II Study of Gemcitabine Versus Docetaxel as First-Line Therapy with Second-Line Crossover in Advanced-Stage Non–Small-Cell Lung Cancer Christian Manegold, Lothar Richard Pilz, Gabriele Koschel, Katrin Schott-von Römer, Jörg Mezger, Dagmar Hruska, Wolfgang Dornof, Helga Gosse, Ulrich Gatzemeier |
|
215-220 |
Efficacy and Safety of Paclitaxel Poliglumex as First-Line Chemotherapy in Patients at High Risk with Advanced-Stage Non–Small-Cell Lung Cancer: Results of a Phase II Study Donald A. Richards, Paul Richards, David Bodkin, Marcus A. Neubauer, Fred Oldham |
|
Translational Medicine | ||
221-223 |
The Role of Mitogen-Activated ERK-Kinase Inhibitors in Lung Cancer Therapy Alex A. Adjei |
|
Clinical Trials | ||
224 |
Selected Phase II Clinical Trials in Lung Cancer CIG Media Group |
|